A new decision tree combining abeta 1-42 and p-tau levels in Alzheimer's diagnosis

Current Alzheimer Research

Volumn 10, Issue 4, 2013, Pages 357-364

  Bombois, Stéphanie ^a,b   Duhamel, Alain ^a,b   Salleron, Julia ^a   Deramecourt, Vincent ^a,b   Mackowiak, Marie Anne ^a,b   Deken, Valérie ^b   Sergeant, Nicholas ^c   Pasquier, Florence ^a,b   Buée, Luc ^c   Sablonnière, Bernard ^a,b   Schraen Maschke, Susanna ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Amyloid peptide; Dementia; Indice; Ratio; Sensitivity; Specificity; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHI SQUARED AUTOMATIC INTERACTION DETECTION; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DECISION TREE; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FRANCE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; POWER ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COHORT STUDIES; DECISION TREES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84878635675     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310040002     Document Type: Article

References (25)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3), 263-9 (2011).
2. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 64, 298-305, (1998).
3. Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, et al. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Exp Neurol; 223,432-438 (2010).
4. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a metaanalysis of 51 studies. J Neurol Neurosurg Psychiatry 80, 966-975 (2009).
5. Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17,90-96 (2010).
6. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta neuropathologica, 121,597-609 (2011).
7. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696-1702 (2003).
8. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA289, 2094-2103 (2003).
9. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology, 52, 1555-1562 (1999).
10. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm116, 203-212 (2009).
11. Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27, 1202-1211 (2006).
12. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393 (2009).
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology,;34, 939-944 (1984).
14. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology,43, 250-260 (1993).
15. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology; 65, 1863-1872 (2005).
16. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology, 51, 1546-1554 (1998).
17. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clinical Chemistry, 47, 1776-1781 (2001).
18. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiological reviews 771081-1132 (1997).
19. Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mechanisms of ageing and development 127,129-132 (2006).
20. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389 (2009).
21. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 78, 468-476 (2012).
22. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. J Alzheimers Dis 31(1): 13-20 (2012).
23. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8(1), 65-73 (2012).
24. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Dis;27, 458-464 (2009).
25. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology,; 72, 1056-1061 (2009).